Literature DB >> 26071871

Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?

Bu Hyeon Yun1, Eu Chang Hwang, Ho Song Yu, Hoseok Chung, Sun-Ouck Kim, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon, Kwangsung Park, Chan Choi.   

Abstract

PURPOSE: To investigate whether histological inflammation detected in an initial prostate biopsy can predict the risk of prostate cancer on a repeat biopsy.
METHODS: This was a retrospective study of 171 patients who underwent repeat prostate biopsy for persistently elevated prostate-specific antigen after an initial negative biopsy result. The enrolled patients were divided into two groups according to the results of the repeat biopsy: the noncancer group (n = 126) and the cancer group (n = 45). Multivariate regression analysis was used to determine the effect of inflammation grade, aggressiveness, and prostate-related parameters on the detection of prostate cancer at the repeat biopsy.
RESULTS: Prostate inflammation grade (p = 0.005) and aggressiveness (p = 0.001) in the initial biopsy were significantly different between the cancer and noncancer groups. Factors associated with the risk of prostate cancer at the repeat biopsy were age [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03-1.14], prostate-specific antigen density (OR 24.30; 95 % CI 9.3-62.9), prostate-specific antigen velocity (OR 1.05; 95 % CI 1.01-1.09), and inflammation aggressiveness (OR 0.05; 95 % CI 0.01-0.27).
CONCLUSIONS: A histological inflammatory finding at the initial prostate biopsy was negatively associated with prostate cancer detection in repeat biopsy. This result could be useful to determine the need for repeat prostate biopsy in patients with persistently elevated prostate-specific antigen.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26071871     DOI: 10.1007/s11255-015-1029-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  28 in total

1.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 2.  Consensus development of a histopathological classification system for chronic prostatic inflammation.

Authors:  J C Nickel; L D True; J N Krieger; R E Berger; A H Boag; I D Young
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

Review 3.  Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management.

Authors:  P J Littrup; S E Bailey
Journal:  Radiol Clin North Am       Date:  2000-01       Impact factor: 2.303

4.  Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997.

Authors:  R O Roberts; E J Bergstralh; M M Lieber; S J Jacobsen
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

5.  Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density.

Authors:  P H Schatteman; L Hoekx; J J Wyndaele; W Jeuris; E Van Marck
Journal:  Eur Urol       Date:  2000-04       Impact factor: 20.096

6.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

7.  Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Authors:  Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Howard L Parnes; Ashraful Hoque; Scott M Lippman; Siobhan Sutcliffe; Sarah B Peskoe; Charles G Drake; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-18       Impact factor: 4.254

8.  Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy.

Authors:  M K Brawer; M A Rennels; R B Nagle; R Schifman; J A Gaines
Journal:  Am J Clin Pathol       Date:  1989-12       Impact factor: 2.493

Review 9.  Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.

Authors:  Giovanni Corona; Linda Vignozzi; Giulia Rastrelli; Francesco Lotti; Sarah Cipriani; Mario Maggi
Journal:  Int J Endocrinol       Date:  2014-02-13       Impact factor: 3.257

10.  Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy.

Authors:  Jung Gon Lee; Seong Ho Bae; Seock Hwan Choi; Tae Gyun Kwon; Tae-Hwan Kim
Journal:  Korean J Urol       Date:  2012-07-19
View more
  3 in total

1.  The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.

Authors:  D M Moreira; D M de O Freitas; J C Nickel; G L Andriole; R Castro-Santamaria; S J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-06-06       Impact factor: 5.554

Review 2.  NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer.

Authors:  Fernando J Velloso; Marina Trombetta-Lima; Valesca Anschau; Mari C Sogayar; Ricardo G Correa
Journal:  Biosci Rep       Date:  2019-04-09       Impact factor: 3.840

Review 3.  From Inflammation to Prostate Cancer: The Role of Inflammasomes.

Authors:  Dev Karan; Seema Dubey
Journal:  Adv Urol       Date:  2016-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.